Zolmitriptan

Zolmitriptan is an antimigraine agent. It binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of Zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system which results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Zolmitriptan is rapidly and well absorbed after oral administration.

Indication:

Zolmitriptan 2.5 is indicated for the acute treatment of migraine with or without aura.

Dosage & Administration:
The recommended dose of Zolmitriptan to treat a migraine attack is 2.5 mg. If symptoms persist or return within 24 hours, a second dose may be taken not less than 2 hours after the first dose. The maximum dose of Zolmitriptan in 24 hours is 10 mg. Zolmitriptan is equally effective whenever the tablets are taken during a migraine attack; although it is advisable that Zolmitriptan tablets are taken as early as possible after the onset of migraine headache. Patients with hepatic impairment: Patients with moderate or severe hepatic impairment a maximum dose of 5 mg in 24 hours is recommended. Patients with renal impairment: No dosage adjustment required.
Use in children: Safety and efficacy of Zolmitriptan in paediatric patients have not been established.
Use in elderly patients: Safety and efficacy of Zolmitriptan in individuals aged over 65 years have not been systematically evaluated.
Side Effects:
Zolmitriptan is well tolerated. Adverse reactions are typically mild/moderate, transient, not serious and resolve spontaneously without additional treatment. The most commonly reported adverse effects are nausea, dizziness, somnolence, asthenia and dry mouth. Disturbances of sensation have also been reported. Heaviness, tightness, pain or pressure may occur in the throat, neck, limbs and chest (with no evidence of ischaemic changes on ECG).
Contraindication:
Zolmitriptan is contraindicated in patients with known hypersensitivity to any components of the product and with uncontrolled hypertension.